摘要
目的观察比较咪唑斯汀和左西替利嗪治疗慢性特发性荨麻疹的疗效和安全性。方法采用随机、双盲、单剂量、平行对照的方法。结果共观察患者170例,咪唑斯汀组85例,左西替利嗪组85例。咪唑斯汀组治疗后第7 d、14 d、28 d有效率分别为82.35%、89.41%、91.76%,左西替利嗪组分别为78.83%、84.71%、89.41%,两组比较差异无显著性(P>0.05)。两种药物的不良反应主要为轻度的口干和困倦。结论咪唑斯汀治疗慢性特发性荨麻疹疗效佳,安全性高,其疗效及不良反应与左西替利嗪相似。
Objective To compare the efficacy and safety of mizolastine and levocetirizine in the treatment of chronic idiopathic urticaria. Method A randomized, double-blind, single-dose, parallel-controlled clinical trial was conducted. Result 170 cases, were evaluated for the effect and safety at the end of the study. The effective rates in mizolastine group and in levocetirizine group were 82.35% and 78.83% on the 7th day after treatment, 89.41% and 84.71%on the 14th day, and 91.76% and 89.41% at the end of the therapy ,respectively. There was no significant difference between the two groups(P〉0.05). The main adverce reactions were mild dry mouth and drowsiness in the two groups. Conclusion The results suggested that mizolastine may be an efficacious and safe drug in the treatment of chronic idiopathic urticaria,and its efficacy and safety can be similar to those of levocetirizine.
出处
《食品与药品》
CAS
2005年第11A期65-67,共3页
Food and Drug